Understanding the PACIFIC Trial
Data from the PACIFIC Trial in Stage 3 Non-Small Cell Lung Cancer
Dr David Spigel provides information on the PACIFIC trial, including the 4-year update.
Exciting Targets Under Study in HCC
Novel Combinations Under Study for HCC
HCC Treatment After Previous I/O Therapy
Choosing Between VEGF TKIs for Frontline HCC Treatment
Atezolizumab/Bevacizumab for HCC: Toxicity Management
Atezolizumab/Bevacizumab Data in Frontline HCC
PD-1/PD-L1 Antibodies and VEGF Inhibitors in HCC
HCC: VEGF TKI Data and Treatment Selection
Targeting the VEGF Pathway in Hepatocellular Carcinoma
Testing for Targetable Mutations in Hepatocellular Carcinoma
Hepatocellular Carcinoma Risk Stratification and Therapy
Optimizing Care for Patients With Hepatocellular Carcinoma
Evolving Approaches for HCC in the Molecular Medicine Era
An in-depth discussion on the targeting of specific molecular pathways with newer, novel therapies to better manage patients with liver cancer.
Case 3: Third-Line Treatment Options for DLBCL
Case 3: Pivotal Trials for DLBCL
Case 3: Later-line Options to Treat Double-Hit DLBCL
Case 3: Relapsed DLBCL, Double Hit
Case 2: Role of L-MIND Regimen as Second-Line Treatment in Transplant Ineligible DLBCL
Case 2: Phase 2 L-MIND Clinical Trial for Relapsed/Refractory DLBCL
Case 2: Considerations for Choosing a Second-Line Therapy for DLBCL
Case 2: Therapeutic Options in Patients With Transplant-Ineligible, Treatment-Refractory DLBCL
Case 2: R-CHOP Refractory DLBCL, Transplant Ineligible
Case 1: Therapeutic Options After CAR T-Cell in Relapsed/Refractory DLBCL
Case 1: Trials in CAR T-Cell for Patients With Relapsed/Refractory DLBCL
Case 1: Therapy for Relapsed DLBCL in Transplant-Eligible Patients
Case 1: Outcomes in Chemotherapy-Treated Patients With DLBCL
Case 1: Identifying Patients for CNS Prophylaxis in DLBCL
Case 1: Waiting for FISH Results in DLBCL